Trials & Filings

Keryx Hits Phase II Targets

Zerenex trial reaches goals in NDD-CKD patients

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Keryx Biopharmaceuticals has posted successful top-line results from its Phase II study of Zerenex (ferric citrate coordination complex) in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with elevated serum phosphorus and iron deficiency anemia. In this study, Zerenex met both its co-primary endpoints,, demonstrating highly statistically significant changes in serum phosphorus and transferrin saturation (TSAT) versus placebo during the 12-week treatment period. In addition, Ze...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters